A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: arbitrate (1), intervene (25), reconcile (7)

DH IVIg approved indications full guidance July 2011

Description
DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audienc
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

Targeting-Shared-Mechanisms-Call-1

Description
Call for Applications: Targeting shared mechanisms in immune-mediated inflammatory diseases Introduction and rationale There are more than 80 autoimmune conditions
Url
/Media/Southampton-Clinical-Research/Downloads/Targeting-Shared-Mechanisms-Call-1.pdf

DH IVIg approved indications summary_May 2012

Description
Demand Management Poster Red Priority - High Short Term Long Term Blue Priority - Medium Short Term Grey Priority - Low Long Term Black
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Summary-Poster-Feb-2106.pdf

ACCORD-2 example sub-protocol

Description
CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Enfortumab-Vedotin-Pembrolizumab

Description
Chemotherapy Protocol UROTHELIAL CANCER Enfortumab vedotin-Pembrolizumab (EV-P) Regimen • Urothelial – Enfortumab vedotin - Pembrolizumab Indication • First-line treatment of adult patients
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Enfortumab-Vedotin-Pembrolizumab.pdf

Mary Barker, Behavioural Science theme co-lead

Description
Auto Generated Title My own research is focused on the development and evaluation of behaviour change interventions to improve diet, nutritional
Url
/ClinicalResearchinSouthampton/Our-people/Behavioural-science-people/Mary-Barker-Behavioural-Science-theme-co-lead.aspx

HSCTRituximab_100mg-7day

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT RITUXIMAB 100mg (Weekly) Regimen • HSCT Allograft - Rituximab (7 day-100mg) Indications • EBV reactivation, PTLD and immune
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTRituximab-100mg-7day.pdf

Azathioprine to treat neurological diseases - patient information

Description
This factsheet contains information about the use of azathioprine to treat neurological diseases, including how the treatment is given and the
Url
/Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Azathioprine-to-treat-neurological-diseases-3153-PIL.pdf

FoM Research Conference programme - final

Description
Faculty of Medicine Research Conference PROGRAMME Tuesday 14th June 2022 Microsoft Teams TIME EVENT SPEAKER 09.15-09.20 MICROSOFT TEAMS
Url
/Media/Southampton-Clinical-Research/Downloads/FoM-Research-Conference-programme-final.pdf
1 to 10 of 23
Previous 1 2 3 Next